UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
Alexion's Wilson Therapeutics Deal Beats Its Synageva Distaster - Bloomberg
Alexion buys Swedish biotech for $855M to broaden rare disease pipeline
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1) (NASDAQ:ALXN) | Seeking Alpha
ALEXION PHARMACEUTICALS, INC. - ALEXION'S NEXT CHAPTER Our Next Chapter & Advances shared mission of following the science and using innovative approaches to develop life-changing medicines for patientsStrengthens AstraZeneca's presence in immunology
Alexion to acquire Wilson Therapeutics for $855 million
AstraZeneca celebrates copper-bottomed deal after Alexion purchase
Alexion Might Finally Satisfy The Market (NASDAQ:ALXN) | Seeking Alpha
Alexion inks $855M takeover of Wilson Therapeutics | Fierce Biotech
WTX101: A Superior Treatment for Wilson Disease
ex995wtxofferstatement
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ALEXION PHARMACEUTICALS, INC.
Alexion in €639m bid for Wilson Therapeutics AB - European Biotechnology
Alexion Pharmaceuticals to acquire Wilson Therapeutics for $855mn
Alexion to Acquire Wilson Therapeutics | Business Wire
Drug Candidate for Wilson Disease Meets Primary Endpoint in Phase III Trial | BioSpace
Chantel Wilson Chase | SpeakerHub
Data backs AZ's Wilson disease drug, but with a question mark | pharmaphorum
AstraZeneca dumps $855M, near-approval rare disease drug
Alexion Acquires Swedish Treatment for Wilson's Disease
Alexion's drug meets primary goal in Phase III Wilson disease trial
Alexion gets rare-disease-focused Wilson
Alexion to acquire Wilson Therapeutics in $855m deal
Wilson Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
ALXN1840 FoCus Phase III Trial in Wilson Disease Met Primary Endpoint Demonstrating Improvement in Copper Mobilisation from Tissues-CliniExpert
